TIDMCNSL

Cambridge Nutritional Sciences PLC

04 December 2023

CAMBRIDGE NUTRITIONAL SCIENCES PLC

("CNS" or the "Company" or the "Group")

CNS continues to expand Scientific Educational Programme and build relationships at leading Industry Events

   --    Company delivers latest webinar tackling the role of inflammation in irritable bowel syndrome 
   --    Lecture presented in Dubai alongside one of India's key opinion leaders on food sensitivity 
   --    CNS continues to raise its profile at key industry events, helping drive demand for products 

CNS (AIM: CNSL), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces developments in its scientific education programme, a key initiative which enables the Company to collaborate with a number of global and UK-based key opinion leaders in the nutritional science field. CNS also highlights the industry events attended recently as it continues its drive to build relationships with healthcare practitioners as well as existing and prospective business partners.

Latest Educational Webinar Released: "Inflammation in irritable bowel syndrome: myth or new treatment target"

-- Thought-leading topic exploring how food IgG antibodies can activate mast cells in the gut leading to irritable bowel syndrome symptoms.

-- In October, CNS's Scientific Director, Dr Nigel Abraham, presented this lecture in person at the International Symposium for food intolerance and Digestive Health ('FIDHC') in Dubai, alongside Mumbai based Dietician and founder of FREEDOM Lifestyle and Wellness Centre, nutrition advisor to the Indian Navy and key opinion leader on food sensitivity testing in India, Dr Naaznin Husein.

CNS Raises Awareness with Practitioners Through Networking at Leading UK Industry Conferences

Key to CNS's strategy of maintaining a leadership position is building awareness with healthcare practitioners. These events give the company the opportunity to meet and re-engage with practitioner customers as well as those who are new to food sensitivity testing or taking their first steps in clinical practice.

IHCAN 2023 Summit

-- CNS's UK team participated in both the November and June IHCAN 2023 summits, the UK's largest integrative health conference and expo held in London.

-- Key industry event, attended by approximately 300 integrative health practitioners and guest speakers from around the world.

-- Opportunity to explain the clinical utility for the Company's products to future practitioners in the end stages of their training.

-- Platform to educate those interested in learning about how embedding food sensitivity testing in their practice can help resolve gut related health issues and improve patient care.

NMI, IPMC, and ION

-- The company also attended several other relevant UK nutrition conferences: Nutritional Medicine Institute ('NMI') in October, the Integrative & Personalised Medicine Congress ('IPMC') in June and the Institute for Optimum Nutrition ('ION') Open Day.

CNS Builds Business Partner Relationships at Industry Trade Fair

Medica

-- In November the Company attended Medica in Germany. The event allowed CNS to meet with existing business partners, whilst also providing the opportunity to connect with potential new partners in currently untapped territories for the Group.

Commenting, Jag Grewal, Chief Executive Officer, said:

"Collaboration with global and UK-based key opinion leaders in the nutritional science field is one of CNS's core values and is a fundamental part of our scientific education programme. As a pioneer in personalised health and nutrition it is vital for us to be leading the way with webinars exploring emerging aspects of science related to gut health , and attending key industry events alongside these high-profile speakers.

"This engagement is critical in our drive to foster strong partnerships with healthcare practitioners and potential business partners. It leads to better awareness and understanding of the Company, which in turn creates demand for our products, and helps cement the Group as a global thought leader in its field."

Contacts:

 
  Cambridge Nutritional Sciences                                      www.cnsplc.com 
   PLC 
  Jag Grewal, Chief Executive                                        via Walbrook PR 
   Officer 
 
  Cavendish Capital Markets                                       Tel: 020 7220 0500 
   Limited 
  Geoff Nash / Edward Whiley / George Dollemore 
   (Corporate Finance) 
  Nigel Birks / Harriet Ward 
   (ECM) 
 
  Walbrook PR Limited                     Tel: 020 7933 8780 or omega@walbrookpr.com 
  Paul McManus / Charlotte Edgar             Mob: 07980 541 893 / Mob: 07884 664 686 
                                                                                   / 
  Sam Allen                                                       Mob: 07502 558 258 
 
 
 

About Cambridge Nutritional Sciences plc

Cambridge Nutritional Sciences plc (AIM: CNSL) is a specialist medical diagnostics company focused on industry-leading Health and Nutrition products.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRANKDBNABDDFBK

(END) Dow Jones Newswires

December 04, 2023 02:00 ET (07:00 GMT)

Omega Diagnostics (LSE:ODX)
Graphique Historique de l'Action
De Oct 2024 à Oct 2024 Plus de graphiques de la Bourse Omega Diagnostics
Omega Diagnostics (LSE:ODX)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024 Plus de graphiques de la Bourse Omega Diagnostics